Medtronic’s CoreValve TAVR system succeeds at 5-year follow-up
Medtronic (NYSE:MDT) presented data this week showing that patients implanted with its CoreValve transcatheter aortic valve replacement system have strong blood flow and improved quality of life at five years post-implant.
The 280-patient Notion trial randomized participants to either surgical or transcatheter aortic valve replacement using the CoreValve system. Data after five years show similar rates of all-cause mortality and superior hemodynamic performance for TAVR compared to surgery.
Medtronic also touted five-year results from a study evaluating its self-expanding CoreValve TAVR system. The company reported that patients implanted with the CoreValve system experienced improvement in their quality of life and sustained low mean gradients.
“These five-year outcomes of the Notion data add to the mounting body of longer-term evidence supporting the effectiveness of TAVR,” Dr. H. Gustav Thyregod, cardiac surgeon in the department of cardiac surgery at The Heart Center in Copenhagen, said in prepared remarks. “We’re pleased to see the strong hemodynamic performance maintained over time without any indication of valve deterioration.”
“It is remarkable to see patients, whose only aortic valve replacement option was to undergo a TAVR procedure, continue to live an improved quality of life five years later,” Dr. Pieter Kappetein, VP & CMO of Medtronic’s heart valve therapies business, added. “While the TAVR therapy continues to show promise in less sick patients, it’s important to acknowledge that the early pioneers of this therapy were those who truly had very limited treatment options. It’s satisfying to see that many of these early patients continue to do well with the self-expanding TAVR platform, especially as the therapy expands to lower-risk patients who are expected to live longer.”
NEXT: AliveCor touts KardiaBand studies